Aktienanalyse zu Gaxos.ai Inc. (GXAI)GXAIGaxos.ai Inc.

Gaxos.ai Inc. develops artificial intelligence applications designed to address opportunities across consumer, enterprise and health-related markets. The Company's operations include Gaxos Labs, which develops and commercializes AI-powered applications, and RNK Health, a majority-owned subsidiary offering personalized weight loss, longevity, and performance treatments. It also holds a strategic minority investment in America First Defense.AI, a defense-technology company developing next-generation counter-UAS and robotic platforms. Gaxos Health integrates AI-driven insights with individual biometric data and health goals to create web and application-based personalized wellness strategies for users. Gaxos Health solutions analyzes a range of health data to provide tailored wellness plans and addresses the growing demand for personalized health solutions. RNK Health is engaged in providing access to certain medications, supplements and other wellness products and services. It operates in the Technology sector (PREPACKAGED SOFTWARE industry).

Gaxos.AI Inc is not a strong buy at this moment due to its current price of $0.39, which is significantly below its 52-week high of $2.63, indicating a substantial decline of 85.2%. Additionally, the stock's RSI is at 38.75, suggesting it is nearing oversold territory but is not yet a clear buy signal. The company has shown improvement in its financials, with a gross margin of 100% in recent quarters, but it also reported a net income loss of $2,172,525 in Q1 2026. The upcoming earnings report on November 12, 2026, could provide more clarity on its performance, but the risks remain high with a year-to-date change of -66.43%.